PTEN and prostate cancer: Histopathologic analysis indicated that loss of CD166 did not significantly change the kinetics of prostate cancer development in Pten null model and all Pb-Cre+;PtenL/L;CD166−/− mice developed adenocarcinoma around 9 weeks of age (Figure 6A and data not shown).